CON ("The window is closed"): In patients with cirrhosis with ascites, the clinical risks of nonselective beta-blocker outweigh the benefits and should NOT be prescribed.
作者信息
Aday Ariel W, Rich Nicole E, Mufti Arjmand R, Tujios Shannan R
机构信息
Department of Internal Medicine, Division of Digestive and Liver Diseases UT Southwestern Medical Center Dallas TX.
出版信息
Clin Liver Dis (Hoboken). 2018 Jun 5;11(5):123-127. doi: 10.1002/cld.699. eCollection 2018 May.
Abstract
摘要
相似文献
1
CON ("The window is closed"): In patients with cirrhosis with ascites, the clinical risks of nonselective beta-blocker outweigh the benefits and should NOT be prescribed.禁忌（“窗户关闭”）：在肝硬化腹水患者中，非选择性β受体阻滞剂的临床风险大于益处，不应开具此类药物。
Clin Liver Dis (Hoboken). 2018 Jun 5;11(5):123-127. doi: 10.1002/cld.699. eCollection 2018 May.
2
PRO ("The Window Is Open"): In patients with cirrhosis with prior variceal hemorrhage and ascites, the clinical benefits of nonselective beta-blockers outweigh the risks and should be prescribed.
Clin Liver Dis (Hoboken). 2018 Jun 5;11(5):119-122. doi: 10.1002/cld.700. eCollection 2018 May.
3
The Beneficial Effect of Beta-Blockers in Patients With Cirrhosis, Portal Hypertension and Ascites.β受体阻滞剂对肝硬化、门静脉高压和腹水患者的有益作用。
Am J Med Sci. 2016 Feb;351(2):169-76. doi: 10.1016/j.amjms.2015.11.018.
4
Assessing the safety of beta-blocker therapy in cirrhosis patients with ascites: A meta-analysis.评估肝硬化腹水患者β受体阻滞剂治疗的安全性：一项荟萃分析。
Liver Int. 2019 Jun;39(6):1080-1088. doi: 10.1111/liv.14040. Epub 2019 Apr 25.
5
Effect of Nonselective β-Blockers on Mortality in Patients With End-Stage Cirrhosis.非选择性β受体阻滞剂对终末期肝硬化患者死亡率的影响。
Ann Pharmacother. 2020 Apr;54(4):322-330. doi: 10.1177/1060028019886529. Epub 2019 Nov 8.
6
Systemic arterial blood pressure determines the therapeutic window of non-selective beta blockers in decompensated cirrhosis.全身动脉血压决定失代偿期肝硬化中非选择性β受体阻滞剂的治疗窗。
Aliment Pharmacol Ther. 2019 Sep;50(6):696-706. doi: 10.1111/apt.15439. Epub 2019 Aug 2.
7
Nonselective Beta-Blockers Do Not Affect Survival in Cirrhotic Patients with Ascites.非选择性β受体阻滞剂不会影响肝硬化腹水患者的生存率。
Dig Dis Sci. 2018 Jul;63(7):1737-1746. doi: 10.1007/s10620-018-5092-6. Epub 2018 May 3.
8
NONSELECTIVE BETA-BLOCKERS IN PATIENTS WITH CIRRHOSIS: "THE THERAPEUTIC WINDOW".肝硬化患者使用非选择性β受体阻滞剂：“治疗窗”
Rev Med Chir Soc Med Nat Iasi. 2016 Jan-Mar;120(1):23-8.
9
Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients.非选择性β受体阻滞剂不会影响肝硬化腹水患者的死亡率：三项随机对照试验的事后分析，共纳入 1198 例患者。
Hepatology. 2016 Jun;63(6):1968-76. doi: 10.1002/hep.28352. Epub 2016 Jan 5.
10
Beta-blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation.肝硬化腹水住院患者使用β受体阻滞剂：死亡率及决定停药和重新用药的因素
Aliment Pharmacol Ther. 2018 Jan;47(1):78-85. doi: 10.1111/apt.14366. Epub 2017 Oct 9.
引用本文的文献
1
HEP-Net opinion on the management of ascites and its complications in the setting of decompensated cirrhosis in the resource constrained environment of Pakistan.HEP-Net关于在巴基斯坦资源有限环境下失代偿期肝硬化患者腹水及其并发症管理的意见。
Pak J Med Sci. 2020 Jul-Aug;36(5):1117-1132. doi: 10.12669/pjms.36.5.2407.
本文引用的文献
1
Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis.预防复发性静脉曲张出血的风险分层：一项个体患者荟萃分析的结果
Hepatology. 2017 Oct;66(4):1219-1231. doi: 10.1002/hep.29267. Epub 2017 Aug 26.
2
Beneficial and harmful effects of nonselective beta blockade on acute kidney injury in liver transplant candidates.非选择性β受体阻滞剂对肝移植候选者急性肾损伤的有益和有害影响。
Liver Transpl. 2017 Jun;23(6):733-740. doi: 10.1002/lt.24744.
3
Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers.普萘洛尔对失代偿期肝硬化患者生存率的影响：一项基于丹麦全国患者登记系统的研究
Liver Int. 2016 Sep;36(9):1304-12. doi: 10.1111/liv.13119. Epub 2016 Apr 4.
4
Red signs and not severity of cirrhosis should determine non-selective β-blocker treatment in Child-Pugh C cirrhosis with small varices: increased risk of hepatorenal syndrome and death beyond 6 months of propranolol use.在伴有小静脉曲张的Child-Pugh C级肝硬化患者中，应根据红色征而非肝硬化的严重程度来决定是否使用非选择性β受体阻滞剂治疗：使用普萘洛尔超过6个月会增加肝肾综合征和死亡风险。
Gut. 2016 Jul;65(7):1228-30. doi: 10.1136/gutjnl-2016-311527. Epub 2016 Mar 2.
5
Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure.非选择性β受体阻滞剂治疗与降低慢加急性肝衰竭患者全身炎症反应严重程度和改善患者生存相关。
J Hepatol. 2016 Mar;64(3):574-82. doi: 10.1016/j.jhep.2015.10.018. Epub 2015 Oct 28.
6
Non-selective β-blockers are associated with improved survival in patients with ascites listed for liver transplantation.非选择性β受体阻滞剂可改善等待肝移植患者腹水的生存率。
Gut. 2015 Jul;64(7):1111-9. doi: 10.1136/gutjnl-2013-306502. Epub 2014 Oct 3.
7
Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis.非选择性β受体阻滞剂会增加肝硬化合并自发性细菌性腹膜炎患者发生肝肾综合征和死亡的风险。
Gastroenterology. 2014 Jun;146(7):1680-90.e1. doi: 10.1053/j.gastro.2014.03.005. Epub 2014 Mar 12.
8
The changing role of beta-blocker therapy in patients with cirrhosis.肝硬化患者β受体阻滞剂治疗作用的变化。
J Hepatol. 2014 Mar;60(3):643-53. doi: 10.1016/j.jhep.2013.09.016. Epub 2013 Sep 26.
9
The window hypothesis: haemodynamic and non-haemodynamic effects of β-blockers improve survival of patients with cirrhosis during a window in the disease.窗口期假说：β受体阻滞剂的血流动力学和非血流动力学效应可改善肝硬化患者在疾病某个窗口期的生存率。
Gut. 2012 Jul;61(7):967-9. doi: 10.1136/gutjnl-2011-301348. Epub 2012 Jan 10.
10
Pathophysiological basis of albumin use in cirrhosis.肝硬化中白蛋白使用的病理生理学基础。
Ann Hepatol. 2011 May;10 Suppl 1:S6-14.
Zotero 插件